HTG Molecular Diagnostics to Announce Year End 2020 Financial Results and Host Conference Call on Thursday, March 25
HTG Molecular Diagnostics (Nasdaq: HTGM) announced it will report financial results for the year ending December 31, 2020, after market close on March 25, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
HTG Molecular Diagnostics (Nasdaq: HTGM) announced it will report financial results for the year ending December 31, 2020, after market close on March 25, 2021. The company will also host a conference call at 4:30 PM Eastern Time to discuss these results and provide a corporate update. HTG specializes in NGS-based molecular profiling, utilizing its proprietary HTG EdgeSeq technology to automate complex molecular profiling from various sample types, aiding in precision medicine.
Details
News Market Reaction – HTGM
The recorded move for HTGM in the trading session of this news was +0.66%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
TUCSON, Ariz., March 16, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM), a life science company whose mission is to advance precision medicine, today announced that it will report its financial results for the year ended December 31, 2020 after the market close on Thursday, March 25, 2021. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 4:30pm Eastern Time.
| Conference Call & Webcast Details | |
| Date: | Thursday, March 25 |
| Time: | 4:30 pm Eastern Time |
| Toll Free: | 877-407-0789 |
| International: | 201-689-8562 |
| Conference ID: | 13715845 |
| Webcast: | http://public.viavid.com/index.php?id=143331 |
About HTG
HTG is focused on NGS-based molecular profiling. The company’s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. HTG’s customers use its technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries, and ultimately to identify treatment options. Its mission is to empower precision medicine.
Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
Phone: (617) 430-7577
Email: arr@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.